Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

E-MTAB-6597

ABSTRACT: A multi-omics approach to decipher the complexity of drug resistance in diffuse large B-cell lymphoma

PROVIDER: E-MTAB-6597 | ExpressionAtlas | 2019-09-09

REPOSITORIES: ExpressionAtlas

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	E-MTAB-6597-analysis-methods.tsv	Tabular
	E-MTAB-6597-analytics.tsv	Tabular
	E-MTAB-6597-atlasExperimentSummary.Rdata	Rdata
	E-MTAB-6597-configuration.xml	Xml
	E-MTAB-6597-g1_g2-mvaPlot.png	Other

Items per page:

1 - 5 of 22

Similar Datasets

A multi-omics approach to decipher the complexity of drug resistance in diffuse large B-cell lymphoma

Project description:A multi-omics approach to decipher the complexity of drug resistance in diffuse large B-cell lymphoma

| PRJEB25633 | ENA

GNPS - Metabolomics Integration with Gene expression profiling Elucidates IL4I1 as Modulator of Ibrutinib Resistance in ABC large B cell Lymphoma

Project description:Drug resistant acute B-cell lymphoma cells were analyzed via LC-MS metabolomics to identify deregulated metabolic pathways that are associated with drug resistance.

2021-03-16 | MSV000087059 | GNPS

Project description:Mutation profiling of drug resistance in diffuse large B cell lymphoma

| PRJNA362349 | ENA

Metabolomics Integration with Gene expression profiling Elucidates IL4I1 as Modulator of Ibrutinib Resistance in ABC large B cell Lymphoma

Project description:Drug resistant acute B-cell lymphoma cells were analyzed via LC-MS metabolomics to identify deregulated metabolic pathways that are associated with drug resistance.

2021-03-16 | MSV000087059 | MassIVE

S63845 resistance mechnism

Project description:MCL-1 plays a central role in B-cell lymphoma progression and drug resistance. Pharmacologically targeting MCL-1, therefore, represents an attractive strategy to combat these lymphomas. S63845, a MCL1 inhibitor, was shown to have high response rates in mantle cell lymphoma (MCL) and burkitt lymphoma.

2022-12-02 | GSE160742 | GEO

Integrative Transcriptomic Analysis Identifies Emetine as A Promising Drug Candidate for Overcoming Acquired Resistance to ALK Inhibitors in Lung Cancer

Project description:Anaplastic lymphoma kinase (ALK) inhibitors (ALKi) are effective in treating lung cancer patients with chromosomal rearrangement of ALK. However, continuous treatment with ALKi invariably leads to acquired resistance in cancer cells. In this study, we propose an efficient strategy to suppress ALKi resistance through a meta-analysis of transcriptome data from various cell models of acquired resistance to ALKi. We systematically identified gene signatures that consistently showed altered expression during the development of resistance and conducted computational drug screening using these signatures. We identified emetine as a promising candidate compound to inhibit the growth of ALKi-resistant cells. We demonstrated that this drug exhibited effectiveness in inhibiting the growth of ALKi-resistant cells, and further elucidated its mode of action through drug-induced RNA-seq data. Our transcriptome-guided systematic approach paves the way for efficient drug discovery to overcome acquired resistance to cancer therapy.

2024-01-09 | GSE252540 | GEO

BRD4 inhibition sensitizes diffuse large B-cell lymphoma cells to ferroptosis

Project description:Diffuse large B-cell lymphoma (DLBCL), the most common form of non-Hodgkin lymphoma, is characterized by an aggressive clinical course. In approximately one-third of DLBCL patients, first-line multi-agent immunochemotherapy fails to produce a durable response. Molecular heterogeneity and apoptosis resistance pose major therapeutic challenges in DLBCL treatment. To circumvent apoptosis resistance, the induction of ferroptosis might represent a promising strategy for lymphoma therapy. Here, a compound library targeting epigenetic modulators was screened to identify ferroptosis-sensitizing drugs. Strikingly, bromodomain and extra-terminal domain (BET) inhibitors sensitized cells of the germinal center B cell-like (GCB) subtype of DLBCL to ferroptosis induction and the combination of BET inhibitors with ferroptosis inducers, such as dimethyl fumarate (DMF) or RSL3, synergized in the killing of DLBCL cells in vitro and in vivo. On the molecular level, the BET protein BRD4 was found to be an essential regulator of ferroptosis suppressor protein 1 (FSP1) expression and to thus protect GCB DLBCL cells from ferroptosis. Collectively, we identified and characterized BRD4 as an important player in ferroptosis suppression in GCB DLBCL and provide a rationale for the combination of BET inhibitors with ferroptosis-inducing agents as a novel therapeutic approach for DLBCL treatment.

2023-08-01 | GSE231871 | GEO

Multi-omics characterization of MEK inhibitor resistant pancreatic cancer based on a genetically engineered mouse model-derived in vitro system

Project description:Tumor heterogeneity and therapy resistance are hallmarks of pancreatic ductal adenocarcinoma (PDAC). Emerging evidence supports treatment-induced resistance to be a multifactorial process mediated by cellular plasticity involving epigenetic regulation. Here, we used a multi-omics approach to analyze in detail molecular mechanisms underlying MEK inhibitor (MEKi) resistance. Therefore, we characterized different cell stages (parental, MEKi resistant, reverted after different passages of drug withdrawal) in primary cell lines derived from a genetic PDAC mouse model, thereby minimizing inter-individual heterogeneity that could distort genome-wide analyses.

2024-01-29 | GSE146348 | GEO

Project description:Multi-drug resistance Salmonella Enteritidis strains

| PRJNA658425 | ENA

Project description:Multi-drug resistance Enterobacter hormaechei sequencing

| PRJNA689971 | ENA